Study of BAY1834942 in Patients With Solid Tumours

Official Title

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Tumour Response Profile of the Anti-CEACAM6 Antibody BAY1834942 in Patients With Advanced Solid Tumours


This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumour response profile of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6) antibody BAY1834942 in patients with advanced solid tumours known to have a prevalence for CEACAM6 expression. The study consists of dose escalation and tumour type-specific expansion in which BAY1834942 will be administered either alone (monotherapy) or in combination with pembrolizumab (combination therapy).

Trial Description

Primary Outcome:

  • Incidence of Treatment-emergent adverse events
  • Severity of Treatment-emergent adverse events
  • AUC(0-504) of BAY1834942 after single dose
  • Cmax of BAY1834942 after single dose
Secondary Outcome:
  • AUC(504),md of BAY1834942 after multiple doses
  • Cmax,md of BAY1834942 after multiple doses
  • Overall response rate (ORR)
  • Leukocyte immune phenotyping
  • CEACAM6 receptor occupancy
  • Cytokine level
  • Ex vivo-stimulated cytokine secretion
  • Concentration of carcinoembryonic antigens (CEA; tumour marker) in blood
The primary objectives of the study are to evaluate and characterize the tolerability and safety profile of repeated doses of BAY1834942 alone or in combination with pembrolizumab, and to characterize the pharmacokinetics of BAY1834942 alone or in combination with pembrolizumab after single dose. Secondary objectives are to evaluate the tumour response profile, pharmacodynamics and pharmacokinetics after multiple doses of the drug.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society